Cargando…
Effectiveness, safety and costs of orphan drugs: an evidence-based review
INTRODUCTION: Several orphan drugs have been approved by the European Medicines Agency (EMA) over the past two decades. However, the drugs are expensive, and in some instances, the evidence for effectiveness is not convincing at the time of regulatory approval. Our objective was to evaluate the clin...
Autores principales: | Onakpoya, Igho J, Spencer, Elizabeth A, Thompson, Matthew J, Heneghan, Carl J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480037/ https://www.ncbi.nlm.nih.gov/pubmed/26109112 http://dx.doi.org/10.1136/bmjopen-2014-007199 |
Ejemplares similares
-
Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials
por: Onakpoya, Igho J, et al.
Publicado: (2019) -
Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports
por: Jefferson, Tom, et al.
Publicado: (2014) -
Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis
por: Rodriguez, Ryan, et al.
Publicado: (2021) -
Impact of heterogeneity and effect size on the estimation of the optimal information size: analysis of recently published meta-analyses
por: Garcia-Alamino, Josep M, et al.
Publicado: (2017) -
Systematic evidence review of rates and burden of harm of intravenous admixture drug preparation errors in healthcare settings
por: Hedlund, Nancy, et al.
Publicado: (2017)